⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8952864 | 0.93 | — | — | |
| SCHEMBL8952885 | 0.93 | — | — | |
| SCHEMBL8952877 | 0.93 | — | — | |
| SCHEMBL5053631 | 0.86 | — | — | |
| SCHEMBL5053625 | 0.86 | — | — | |
| SCHEMBL5053627 | 0.86 | — | — | |
| SCHEMBL8952803 | 0.86 | NR1I2 (0.53) | — | |
| SCHEMBL8952812 | 0.86 | NR1I2 (0.53) | — | |
| SCHEMBL8952817 | 0.86 | NR1I2 (0.53) | — | |
| SCHEMBL27508395 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | claimed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | claimed |
| EP-1551791-A4 | NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS | ATHEROGENICS INC (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1551791-A1 | NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS | Atherogenics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1451138-A4 | METHODS OF REVERSING AND PREVENTING CARDIOVASCULAR PATHOLOGIES | ATHEROGENICS INC (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1451138-A2 | METHODS OF REVERSING AND PREVENTING CARDIOVASCULAR PATHOLOGIES | Atherogenics, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| WO-2004024094-A2 | METHODS AND COMPOSITONS FOR THE USE OF D-MALIC ACID TO DECREASE SERUM TRIGLYCERIDE, CHOLESTEROL, AND LIPOPROTEIN LEVELS | SAMFORD UNIVERSITY (US) | 2004-03-25 | — | — | WO | disclosed |
| EP-1385501-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2004007423-A1 | NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS | ATHEROGENICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003039352-A2 | METHODS OF REVERSING AND PREVENTING CARDIOVASCULAR PATHOLOGIES | ATHEROGENICS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002087556-A9 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS INC (US) | 2003-03-20 | — | — | WO | disclosed |
| EP-1272465-A2 | COMPOUNDS AND METHODS TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | Atherogenics, Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002087556-A2 | PROBUCOL MONOESTERS AND THEIR USE TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2001077072-A2 | COMPOUNDS AND METHODS TO INCREASE PLASMA HDL CHOLESTEROL LEVELS AND IMPROVE HDL FUNCTIONALITY | ATHEROGENICS, INC. (US) | 2001-10-18 | — | — | WO | disclosed |